By Elisabeth Mahase Taken Directly from the BMJ doi: https://doi.org/10.1136/bmj.n1898 Criticisms of the US Food and Drug Administration’s accelerated approval process have resurfaced after the recent…
View More FDA allows drugs without proven clinical benefit to languish for years on accelerated pathway
By Syed Ghias Take Home Messages Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are a novel class of oral hypoglycaemic medications which have been shown to be effective…
View More Sodium-glucose co-transporter 2 inhibitors – new frontier in the treatment of heart failure
By Ahmed El-Medany In contrast to their prevalence in the overall disease population, Black individuals were considerably underrepresented in trials that affirmed the United States’…
View More Underrepresentation of black participants in key Cardiology trials
By Ahmed El-Medany In a large retrospective study by Venetsanos et al, researchers analysed 37,990 patients from the SWEDEHEART registry with myocardial infarction (MI) who…
View More Prasugrel and ticagrelor associated with similar efficacy and safety following myocardial infarction
Day Two, as reported by three BCS members in attendance
View More ESC Congress 2020 – The Digital Experience
Day One By Dr Noor Sharrack, Cardiology SpR With public gatherings banned in the Netherlands due to the COVID-19 pandemic, the 2020 edition of the…
View More ESC Congress 2020 – The Digital Experience